Order Article Reprints

Günther T, Holzleitner N, Di Carlo D, Urtz-Urban N, Lapa C, Wester H-J. Development of the First ¹⁸F-Labeled Radiohybrid-Based Minigastrin Derivative with High Target Affinity and Tumor Accumulation by Substitution of the Chelating Moiety. Pharmaceutics. 2023; 15(3):826. https://doi.org/10.3390/pharmaceutics15030826

Günther, Thomas, Nadine Holzleitner, Daniel Di Carlo, Nicole Urtz-Urban, Constantin Lapa, and Hans-Jürgen Wester. 2023. "Development of the First ¹⁸F-Labeled Radiohybrid-Based Minigastrin Derivative with High Target Affinity and Tumor Accumulation by Substitution of the Chelating Moiety" Pharmaceutics 15, no. 3: 826. https://doi.org/10.3390/pharmaceutics15030826

Günther, T., Holzleitner, N., Di Carlo, D., Urtz-Urban, N., Lapa, C., & Wester, H.-J. (2023). Development of the First ¹⁸F-Labeled Radiohybrid-Based Minigastrin Derivative with High Target Affinity and Tumor Accumulation by Substitution of the Chelating Moiety. Pharmaceutics, 15(3), 826. https://doi.org/10.3390/pharmaceutics15030826